CJC-1295 with DAC
Molecular Formula : C165H269N47O46
Molecular Weight : 3647.15
CAS No. : 863288-34-0
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 (Drug Affinity Complex)
CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog.
One of the advantages of CJC-1295 over traditional GHRH rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.
Clinical Research was first conducted fCJC-1295 during the-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful fmost research subjects.
CJC-1295 is a tetrasubstituted peptide analogue of GHRH with D-Ala, Gln, Ala, Leu substitutions at positions 2, 8, 15, 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, position 27 to prevent methionine oxidation. These substitutions are key in increasing the overall half life of CJC-1295 but there lies an even greater reason as to why the half life has been extended from ~7 minutes to greater than 7 days! Bioconjugation is a relatively newer technology that takes a reactive group attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to form a more stable bond. Albumin, one of the most abundant substances in the human body is chosen as the nucelophile by this particular peptide thanks to a Cys34 thiol group that attracts it. By combining the tetrasubstituted GHRH analogue with maleimodoproprionic acid using a Lys linker, you create a GHRH peptide with a high binding affinity falbumin. Once the CJC-1295 molecule has attached itself to albumin, it is given an extended half life bioavailability thanks to the albumin preventing enzymatic degredation kidney excretion. In fact, bioconjugation is so effective that there was less than 1% of CJC-1295 left unreacted in vivo over 90% was stabilized after subQ admin. This means that you get more of what you paid fworking f you. There was no DPP-IV degredation observed on CJC-1295 in any of the various experiments conducted.
THESE PRODUCTS ARE SOLD FRESEARCH PURPOSES ONLY.